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Stroke is the leading cause of adult disability, but there is no drug regimen available that 
promotes recovery after stroke. Recovery of function after stroke involves molecular signaling 
events mediated by cAMP and cGMP signaling, such as CREB activation and axonal sprouting. 
Cyclic nucleotide signaling is regulated by a variety of phosphodiesterase (PDE) isoforms, 
which degrade cAMP and cGMP and exhibit region-specific distribution in the brain. PDE10A is 
highly enriched in the basal ganglia/striatum. A novel PDE10A inhibitor, TAK-063, was tested for 
its effect on functional recovery and neuroplasticity after both striatal and cortical stroke. 
Inhibition of PDE10A improves recovery of function after striatal but not cortical stroke, 
consistent with its brain distribution, in young adult mice. Recovery of motor function correlated 
with increases in striatal BDNF, downstream of the cAMP signaling cascade, as well as axonal 
sprouting and angiogenesis. However, PDE10A inhibition did not improve functional recovery in 
aged mice after striatal stroke. PDE2A is the most prevalent phosphodiesterase expressed in 
cortex. A second novel PDE inhibitor specific to PDE2A, PDE2A-T1, was tested for its effect on 
tissue repair and functional gains after cortical stroke. PDE2A-T1 treatment improved behavioral 
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outcomes in both young adult and aged mice after stroke and increased the density of cortical 
axonal connections in aged animals after stroke. This is the first demonstration of brain region-
specific enhanced functional recovery after stroke, and indicates that differential molecular 
signaling between brain regions can be exploited to improve recovery based on stroke subtype, 
with an important effect of age on therapeutic efficacy.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  	  
	   iv	  
The thesis of Nora Abduljawad is approved.  
Amy Catherine Rowat  
Rachelle Hope Watson, Co-Chair  
Stanley Thomas Carmichael, Co-Chair 
 
 
University of California, Los Angeles  
2019  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  	  
	   v	  
Table of Contents  
 
Abstract ………………………………………………………………………………………………… ii  
Committee Page ………………………………………………………………………………………. iv 
Table of Contents ……………………………………………………………………………………… v 
List of Tables & Figures.………………………………………………………………………………. vi 
Acknowledgments …………………………………………………………………………………….. vii 
Introduction …………………………..………………………………………………………………... 1 
Materials & Methods ………………………………………………………………………………….. 9 
Results ………………………………………………………………………………………………… 15 
Discussion ……..……………………………………………………………………………………… 23 
Figures ……………………………………………………………………………………………….... 40  
References ……………………………………………………………………………………………. 50 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  	  
	   vi	  
 
List of Figures 
 
Figure 1: Functional effect of TAK-063 on forelimb use and gait post-striatal and cortical stroke 
in young adult mice …………...…………...…………...…………...…………...…………...……… 40 
Figure 2: TAK-063 treatment-mediated alterations in BDNF expression in striatal tissue ……. 41  
Figure 3: Motor connections post-striatal stroke and TAK-063 treatment ..………….,,…...…... 42 
Figure 4: Effects of PDE10A inhibition on angiogenesis, neurogenesis, and gliogenesis in post-
striatal stroke ………...…………...…………...…………...…..………...…………...…………….... 43 
Figure 5: Degree of infarct size in TAK-063-treated mice ……...…………...…………...………. 44 
Figure 6:  Functional effect of TAK-063 on gait post-striatal stroke in aged mice …………….. 45 
Figure 7: Functional effect of PDE2A-T1 on gait, spontaneous forelimb use, and skilled reach 
after cortical stroke in young adult and aged mice ………...…………...…………...……………. 46 
Figure 8: PDE2 inhibition increases peri-lesional axonal connections in aged mice after cortical 
stroke ………...…………...…………...…………...…..………...…………...…………...………….. 47 
Figure 9: PDE2 inhibition does not enhance early-phase cell progenitor proliferation in peri-
lesional cortex after stroke in aged mice ………...…………...…………...…………...………….. 48 
Figure 10: Degree of infarct size in PDE2A-T1 treated aged mice ……………………………… 4 
 
 
 
 
 
 
 
 
	  	  
	   vii	  
Acknowledgments 
I would like to acknowledge Shyama Nair and Dr. Shirin Birjandi for their contributions to this 
work, as well as Takeda Pharmaceuticals for providing funding support and novel 
phosphodiesterase inhibitors. I also wish to acknowledge my mentor, Dr. Tom Carmichael, the 
members of my thesis committee, and past and present members of the Carmichael lab for their 
invaluable support and scientific guidance.
	  	  
	   1	  
Introduction 
Globally, 15 million people suffer a stroke each year [1]. In the United States, stroke 
burdens 800,000 new patients annually, with 80% suffering ischemic lesions caused by a 
blockage of blood vessels and disruption of blood flow to the brain [2]. Improvements in acute 
care, such as the development of thrombectomy procedures and intravenous thrombolytic 
treatments, have led to reductions in ischemic stroke-related mortality [1,3]. However, damage 
to the brain occurs rapidly, leading surviving patients to suffer serious, long-term losses in 
cognitive, motor, and linguistic functionalities [4-6, 63]. As a result, stroke has become a leading 
cause of adult disability worldwide [1,6]. Moreover, this stroke disability can be progressive, 
since initial functional gains made with neurorehabilitation are often lost, as patients gradually 
minimize their use of affected functions [3]. Despite this great burden, there is currently no drug 
treatment that promotes neural repair or functional recovery after stroke. Developing 
pharmacological treatments for this chronically disabling disease is thus a strong research 
priority. 
Disruption of blood flow to brain tissue results in initial cell death and damage. However, 
the brain also has a limited ability for subsequent repair after stroke. The progression of cell 
death in the stroke core, or infarct, results in the release of cytokines and diffusible free radicals 
that alert neighboring cells to initiate a neural repair response [7-10]. Spatially, stroke thus 
comprises a focal site of permanent, irreparable cell death, surrounded by areas of 
reorganization and plasticity in adjacent, peri-infarct tissue. The neuroplasticity or repair 
program induced in this peri-infarct tissue includes an integrative, coordinated response across 
multiple cell types and scales, spanning synapse to circuit. Dendritic spine morphogenesis, 
physiological alterations in neuronal excitability, generation of new neurons and their migration 
to areas of injury, formation of new blood vessels, recruitment and differentiation of glial cells, 
activation of neuronal growth programs leading to formation of new axonal connections, and 
functional re-mapping of cortical circuits are all processes that participate in the brain’s 
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response to stroke in animal models or humans [7, 11-17]. However, the extent to which these 
repair processes occur endogenously remains limited in time and scope after stroke [3, 13, 16]. 
Consequently, this endogenous repair program is insufficient to produce full repair and 
recovery. The goal of ongoing research programs is to identify mechanisms that extend or 
increase the amount of early post-stroke plasticity, or re-activate plasticity programs at later 
stages after stroke. Boosting the brain’s repair potential in this way would produce more 
sustained neural repair and potentially greater, lasting functional improvement. 
Developing effective therapeutics for stroke might begin with recognizing the similarities 
between the processes participating in post-stroke neural repair and the systems governing 
plasticity during regular learning and memory formation [3, 18-21]. On a molecular level, both 
learning and post-stroke recovery are associated with gene expression changes in signaling 
pathways involving Nogo/Nogo receptors, GAP-43, c-Jun, MARCKS, stathmin, and RB3 [4, 13, 
22-23]. As described above, recovery also involves cellular events such as dendritic spine 
plasticity and neurogenesis, as well as long-term potentiation-dependent changes in synaptic 
activity, events with well-characterized roles in memory formation [23-25]. At the circuit level, 
both recovery after stroke and learning involve honing down diffuse networks of connected brain 
regions to sets of core areas directly involved in specific tasks [3]. Even cognitively, functional 
recovery requires “re-learning” tasks lost due to stroke, a process that relies on the same 
neuropsychiatric principles that mediate learning for the first time [26]. These parallels have led 
to the hypothesis that repair and recovery after stroke might depend on the brain’s ability to 
harness systems that mediate structural and functional plasticity during normal learning and 
memory formation. 
This hypothesis was initially tested using non-stroke specific drugs that enhance learning 
potential broadly, such as serotonin reuptake inhibitors, dopamine agonists, and various central 
nervous system stimulants [12, 27]. Clinical trials employing these compounds failed, likely due 
to the action of these drugs on neurotransmitter systems not primarily implicated in stroke-
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induced damage or recovery [12, 27]. As a result, ongoing work has instead shifted towards 
characterizing the molecular learning and memory systems specifically altered or recruited after 
stroke, as well as developing therapeutics to target these context-relevant systems. 
Two neurotransmitter systems that impact synaptic plasticity in learning and memory 
have been implicated in recovery after stroke. The first of these is tonic, or extrasynaptic, 
inhibitory GABA signaling [20, 28]. During traditional learning, blocking tonic GABA signaling 
promotes neuronal excitability in the hippocampus and enhances learning and memory in many 
animal models [30, 31]. After stroke, tonic GABA inhibition is reported to increase and persist, 
likely due to downregulation of GABA transporters in astrocytes [32]. Under physiological 
conditions, astrocytes help maintain neurons in their excitable state, partially by uptake of 
excess GABA from the extracellular environment. This reduced GABA uptake and resulting 
dampened neuronal excitability is protective in the acute setting after stroke, since stroke 
causes a positive feedback cycle of excitotoxicity-mediated neuronal death [7, 12, 29]. However, 
following this initial period of cell death, reduced neuronal excitability hinders the brain’s 
capacity for plasticity and repair [12, 20, 21]. One context-relevant system that has been 
targeted as a post-stroke therapeutic is tonic GABA inhibition; both genetic deletion and 
pharmacological antagonism of tonic GABA receptors improves functional recovery and 
promotes cortical circuit reorganization in animal models of stroke [20].  
     A second neurotransmitter system with dual roles in learning and stroke recovery is 
excitatory glutamatergic signaling through AMPA receptors (AMPARs). Trafficking of AMPARs 
to synapses is a key step in the induction and maintenance of long-term potentiation (LTP), the 
cellular correlate of learning and memory formation in the brain [33, 34]. Drugs that enhance 
glutamatergic transmission through AMPAR signaling increase neuronal excitability and improve 
learning in humans and animal models [35, 36]. After stroke, dampened neuronal excitability 
resulting from increased tonic GABA inhibition might be offset by potentiation of excitatory 
AMPAR signaling. Preclinical studies have demonstrated that treatment with positive allosteric 
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modulators of AMPARs after stroke does in fact promote functional recovery, as well as peri-
infarct induction of BDNF, a neurotrophin that causally regulates multiple aspects of cortical 
plasticity such as neurogenesis, neuronal circuit reorganization, and dendritic spine 
morphogenesis [37-39]. Together, studies of tonic GABA and AMPAR signaling in stroke 
demonstrate that learning and memory systems that enhance peri-infarct excitability are 
effective, context-appropriate therapeutic targets for stroke recovery and repair. 
Within neurons, a central molecular node that regulates excitability and firing potential is 
the transcription factor CREB (CRE response element binding protein) [40-42]. A wide range of 
cellular inputs lead to intracellular signaling cascades that converge upon downstream CREB 
activation. The resulting CRE-dependent transcription increases neuronal excitability and 
synaptic restructuring [40, 44]. In this way, CREB couples experience-dependent neuronal 
stimulation with gene transcription and long-term cellular and molecular changes associated 
with plasticity, learning, and memory [45, 46]. This role for CREB has been well-appreciated in 
the learning and memory field. CREB has been shown to be necessary for LTP and long-term 
memory maintenance; CREB potentiation also enhances performance in a wide range of 
learning and memory paradigms, indicating a role that is non-specific to particular types of 
learning [47-50]. Thus, like tonic GABA inhibition and AMPAR transmission, CREB is a 
molecular target that increases neuronal excitability, with learning and memory functions that 
could be co-opted for stroke repair. 
Importantly, CRE-dependent transcription has additional roles in the allocation of 
neurons into a memory’s trace or engram, defined as the cluster of neurons that co-activate to 
encode or store a particular memory [51-56]. In other words, CREB expression during learning 
preferentially commits neurons to an active neuronal ensemble that comprises the circuit-level 
representation of memory. Selective ablation of these neurons disrupts this particular memory 
[57]. CREB might allocate neurons into other types of task-specific engrams or circuits, such as 
the motor circuit for a particular limb movement, or the sensory circuit for a particular type of 
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visual stimulus [18, 58-60]. Critically, CREB mediates reorganization of these task-specific 
neuronal circuits in response to altered input or experience [45, 61-62]. For example, rodent 
monocular or whisker deprivation paradigms promote CREB-dependent reorganization of the 
neuronal networks that represent visual or somatosensory information, respectively [62-64]. In 
human studies of blind individuals, brain areas exhibiting reorganization of functional 
connectivity, such as traditional visual processing areas, show increased CREB expression, 
suggesting a role for CREB in mediating the network reorganization observed in these areas 
[65]. This re-organization role is particularly relevant to the context of repair after stroke. Stroke 
causes task-specific neuronal engrams to be disrupted, either directly due to death of 
participating neurons or indirectly via functional disconnection or lack of coincident firing of 
surviving neurons [15, 66-68]. Activation of CREB in surviving neurons after stroke might be one 
molecular way to encourage neuronal excitability and circuit reorganization, which is correlated 
in both preclinical and human studies with greater post-stroke functional recovery. 
Recent preclinical studies have focused on testing this idea, to establish whether CREB 
can enhance the limited endogenous plasticity observed after stroke and promote functional 
recovery [18]. In these studies, CREB levels were manipulated virally in a subset of peri-infarct 
neurons after stroke to the motor cortex. Upregulation of CREB after stroke improved motor 
function on a variety of motor assessments. Further, selective inactivation of CREB-transfected 
neurons after stroke resulted in the loss of initial CREB-induced functional gains, to the point of 
worsened performance even beyond untreated stroke controls. Releasing this selective 
inactivation reinstated the initial motor improvement. This functional recovery was correlated 
with both structural and functional plasticity of cortical networks. In addition to increased axonal 
sprouting and connectivity within spared cortical motor regions, viral up-regulation of CREB 
resulted in accelerated remapping of lost motor or sensory functions into adjacent, surviving 
pre-motor and somatosensory regions. Further, neuronal CREB induction activated sets of 
genes within cellular pathways that include nervous system development and tissue 
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development, highlighting the critical status of CREB as a transcription factor able to regulate 
cellular processes relevant to stroke repair as well as learning and memory. Together, these 
results show that CREB is a molecular switch that can turn recovery on or off, by altering 
neuronal transcriptional profiles in ways that promote cortical circuit plasticity after stroke. These 
studies thus identify CREB as a specific learning and memory molecule that can accelerate or 
enhance endogenous plasticity mechanisms after stroke. 
    Currently, there is no drug regimen available that promotes neural repair or functional 
recovery after stroke. A compound able to target CREB pharmacologically could have strong 
clinical potential as a post-stroke therapeutic. One intracellular signaling cascade that activates 
CREB and involves druggable molecular targets is the cyclic nucleotide/protein kinase pathway 
[69, 70]. In this pathway, activation of G protein-coupled receptors on a cell’s surface prompts 
adenylyl and/or guanylyl cyclase to synthesize cyclic nucleotides via conversion of AMP/GMP to 
their cyclic forms cAMP/cGMP, respectively. In turn, cyclic nucleotides act as intracellular 
second messengers and activate protein kinases, which translocate to the cell’s nucleus to 
phosphorylate CREB and other transcription factors. Phosphorylation of CREB at the serine-133 
site results in CREB-dependent transcription of plasticity-related genes, such as BDNF [70]. 
Within this and other cyclic nucleotide signaling cascades, phosphodiesterases (PDEs) are the 
sole enzymes that hydrolyze the second messengers cAMP and cGMP, thus regulating the 
duration and amplitude of cyclic nucleotide signaling [71]. Inhibiting PDEs prevents the 
degradation of cyclic nucleotides and is one way of increasing cyclic nucleotide availability for 
intracellular signaling. This signaling includes participation in pathways that potentiate CREB 
phosphorylation and CREB-mediated transcription. A variety of pharmacological PDE inhibitors 
have been developed and can increase cyclic nucleotide signaling in multiple tissue types, 
including the brain [72, 73]. Currently, these PDE inhibitors are clinically approved for the 
treatment of acute heart failure, pulmonary hypertension, and erectile dysfunction [74-76]. 
Increasing preclinical evidence indicates that PDE inhibitors can also improve performance on 
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learning and memory tests, as well as attenuate disease progression in a variety of neurological 
diseases, such as schizophrenia and Alzheimer’s disease [77, 78].  
    Phosphodiesterases comprise a superfamily of enzymes encoded by 21 genes [79]. This 
family is further divided into 11 sub-families (PDE1 through PDE11) based on sequence 
homology, structural features, catalytic properties, and substrate affinity for cAMP, cGMP, or 
both. Further, each PDE family includes multiple mRNA splice variants, giving rise to over 100 
different PDE isoforms in total. Importantly, PDE families and their isoforms are expressed in 
tissue- and cell-type specific manners [80]. For example, PDE1 and PDE3 are the most 
prevalent PDEs expressed in the heart, while PDE8 is the dominant PDE in thyroid tissue [80]. 
Within the brain, PDE10 is maximally expressed in the striatum/basal ganglia, and PDE2 is the 
most abundant PDE isoform expressed in the hippocampus as well as cortical regions [71, 80]. 
Both striatum and cortex are common sites of human stroke [81]. This regional distribution of 
PDEs and opportunity for region-specific targeting make PDEs an especially popular 
pharmacological target broadly; in the context of stroke, this allows for selective manipulation of 
cyclic nucleotide signaling, as well as potential downstream CREB activation and repair-
associated plasticity events, in affected stroke regions and circuits. Due to the diversity of 
human stroke subtypes, treatments tailored to specific stroke pathologies could have increased 
clinical potential through reduced side effects and potentially improved, focused efficacy in 
affected brain regions.   
    The current study first aimed to test the efficacy of pharmacological phosphodiesterase 
inhibition in enhancing functional recovery after stroke. This was performed in two preclinical 
models of ischemic stroke, to investigate whether selective targeting using different PDE 
inhibitors could promote region-specific recovery based on stroke subtype. In previous work, a 
novel, striatum-specific PDE10A inhibitor, TAK-063, was tested in a model of striatal stroke as 
well as a separate model of cortical stroke. Treatment with TAK-063 ameliorated motor deficits 
following striatal but not cortical stroke. The current study demonstrated that, unlike with 
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striatum-specific PDE10A inhibition, cortex-specific PDE2A inhibition using the novel inhibitor 
PDE2A-T1 improved motor recovery following cortical stroke in both young adult and aged 
mice.  
    This study next aimed to identify potential cellular and molecular mechanisms underlying the 
functional recovery induced by targeted PDE inhibition. Following striatal stroke, striatum-
specific PDE10A inhibition increased peri-infarct protein levels of BDNF, a neurotrophin induced 
downstream of CREB activation and correlated with neural repair and recovery, as well as 
angiogenesis in contralesional striatum and axonal connectivity of motor cortex with 
contralesional striatum. Following cortical stroke, cortical PDE2A inhibition increased axonal 
connections within peri-infarct motor systems, consistent with previous studies demonstrating 
the role of CREB in enhancing axonal sprouting and cortical circuit reorganization after stroke. 
No changes in infarct size, post-stroke neurogenesis, gliogenesis, or microglial proliferation 
were observed with either treatment. Together, these studies comprise the first demonstration of 
region-specific functional recovery after stroke, and demonstrate that differential molecular 
signaling between brain regions can be exploited to improve recovery based on stroke subtype. 
These studies also demonstrate that PDE inhibitors can be administered systemically to 
promote plasticity processes that act downstream of CREB activation, a molecular learning and 
memory target that enhances neuronal excitability, neural repair, and functional recovery after 
stroke.  
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Materials and Methods  
 
Animals 
All procedures were performed in accordance with National Institutes of Health Animal 
Protection Guidelines. 10-week old male C57BL/6 mice from Jackson Laboratories (Bar Harbor, 
MA) were used for young adult studies. 18-month old male C57BL/6 mice obtained from the 
National Institute of Aging (NIA) were used for aged studies. Animals were housed under 
pathogen-free conditions in a light-controlled environment with a reverse light cycle, with free 
access to irradiated pellets (LabDiet PicoLab, Rodent Diet 20) and sterilized, acidified water. 
Housing temperatures were maintained between 69 to 70˚ F and standard humidity between 30 
to 70%.  
 
TAK-063 Preparation 
Lyophilized TAK-063, a PDE10-specific inhibitor, was obtained from Takeda Pharmaceuticals. 
TAK-063 was solubilized in a solution of 0.5% methyl cellulose (MC) in sterile saline. A stock 
solution of 5 mg/ml TAK-063 was made fresh twice weekly. The solution was vortexed and 
sonicated for 20 min in an ultrasonic bath, with intermittent vortexing during sonication, and kept 
at 4C. Further dilutions were made using MC saline as needed. Diluted solutions were 
sonicated for 10 minutes prior to drug injection.  
 
PDE2A-T1 preparation 
Lyophilized PDE2A-T1, a PDE2-specific inhibitor, was obtained from Takeda Pharmaceuticals. 
PDE2A-T1 was solubilized step-wise in 10% DMSO, 10% Cremophor EL, 30% PEG 400, 10% 
propylene glycol, and 40% H2O. At each step, the PDEA-T1 solution was vortexed. After 
addition of H2O, the solution was vortexed until completely translucent. Fresh PDE2A-T1 
solution was prepared twice weekly. Once daily, 50 uL of either vehicle or 3.0 mg/kg PDE2A-T1 
solution was injected intraperitoneally into test subjects. Daily injections were initiated five days 
after stroke. 
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Drug delivery 
Daily intraperitoneal injections of drug or vehicle were initiated 5 days after stroke induction. 
TAK-063 was injected at escalating doses of either 0.3 mg/kg, 3.0 mg/kg, or  10.0 mg/kg. 
PDE2A-T1 was injected at 3.0 mg/kg. No adverse health effects were observed over the course 
of drug treatment.  
 
Stroke production: L-NIO Injection 
Mice were anesthetized with 2.5% isoflurane and placed in a stereotaxic apparatus. The left 
common carotid artery was exposed through a ventral midline incision in the neck, which was 
shaved and aseptically prepared. After separation of the artery from the vagus nerve, the artery 
was permanently occluded via  cauterization. Mice were subsequently placed on a stereotaxic 
apparatus where their heads were also shaved and aseptically prepared. Skulls were exposed 
using a midline incision. A single burr hole was made in the skull (0.95 AP, 3.0 ML). A 33-gauge 
needle fitted to a 25 uL Hamilton syringe was angled at 10° over the burr hole. 3uL of the 
vasoconstrictor L-NIO (27mg/mL) was infused at a rate of 0.3uL/min into the brain (0.95 AP, 3.0 
ML, 2.6 DV). Five minutes after injection, the needle was retracted and the incision was closed. 
Body temperature was monitored and maintained at 37°C (±3°C) during the procedure. 
  
Cortical stroke production: Photothrombosis 
Mice were anesthetized with 2.5% isoflurane and placed in a stereotaxic apparatus. Heads were 
shaved and aseptically prepared. Skulls were exposed using a midline incision. Each mouse 
was injected with 200 uL of a sterile solution of 10 mg/mL Rose Bengal in PBS. After 5 minutes, 
a 200 mV light source was shone focally onto forelimb motor cortex (AP 0.0, ML 1.5, DV 0.0) for 
15-18 minutes. The skull was rinsed using sterile solution, and the incision was closed. Body 
temperature was monitored and maintained at 37°C (±3°C) during the procedure. 
  
	  	  
	   11	  
5-Ethynyl-2’deoxyuridine preparation 
A stock solution of 5 mg/ml of 5-ethynyl-2’deoxyuridine (EdU) was prepared in potable water. 
EdU, along with the antibiotic trimethoprim–sulfamethoxazole (TMS), was added to mouse 
drinking water days 3-10 after stroke, for a final EdU concentration of 200 ug/mL. Water was 
refreshed every 48 hours.  
 
BDA Injections 
10 weeks after stroke, the neuroanatomical tracer biotinylated dextran amine (BDA, 10k MW, 
Invitrogen) was injected into motor cortex ipsilateral to the cortical stroke site. Following 
anesthesia with 2.5% isoflurane and placement in a stereotaxic apparatus, a burr hole was 
made in the skull 0.0 mm anterior and 1.5 mm lateral to bregma. Using a Hamilton syringe and 
automated injection apparatus, 0.3 uL of BDA was infused at a rate of 0.03 uL/min, 0.75mm 
ventral to the surface of the brain. Body temperature was monitored and maintained at 37°C 
(±3°C) during the procedure. Animals were euthanized 1 week after BDA injections.  
 
Behavioral Testing 
Motor performance on three different behavioral tests was assessed at regular intervals 
following stroke, beginning 1 week after injury. The grid walking and cylinder tests, administered 
monthly, assessed gait and spontaneous forelimb use, respectively. The pasta matrix test, 
administered bimonthly in the aged PDE2A-T1 studies, measured skilled reach ability. Mice 
were trained on the pasta matrix for 5 weeks prior to injury. Motor performance on each task 
was normalized to pre-stroke baseline performance. Mice were tested up to 9 weeks post-
stroke, a time point that precedes spontaneous motor recovery. Sample size was 10-12 animals 
for young adult studies and 8-10 animals for aged studies.  
 
Grid-walking Task 
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Mice were placed on a suspended wire grid and video recorded while walking freely for 5 
minutes each. The total grid area was 32 cm x 20 cm, with 1 cm x 1 cm squares. Videos were 
subsequently analyzed offline by evaluators blinded to the treatment groups. Total number of 
steps taken and the total number of foot-faults by the stroke-affected forelimb, defined as total 
slips through the grid, were recorded. Number of foot-faults was reported as percentages of 
total steps taken and normalized to pre-stroke baseline performance.  
  
Cylinder Task 
Mice were placed in a transparent, plastic cylinder (15 cm x 10 cm) and video recorded for 5 
minutes to capture exploratory vertical rearing behavior onto the cylinder. Two mirrors were 
placed at angles vertically behind the cylinder to allow the video camera to capture rears in the 
opposite plane of view. Videos were subsequently analyzed offline by evaluators blinded to the 
treatment groups. The number of vertical rears made using the right forelimb, left forelimb, or 
both forelimbs was determined to determine forelimb preference during spontaneous, 
exploratory behavior. Preference for use of the stroke-affected limb was calculated as: (right 
rears - left rears/total rears) and normalized to pre-stroke baseline performance.  
 
Pasta Matrix Task  
Mice were placed in a plastic chamber and were trained to reach through a narrow slit in the 
chamber to break and retrieve pieces of dry pasta. Dry capellini pasta was cut into 3.2-cm 
pieces and oriented vertically on a heavy-duty plastic block with holes drilled in that fit individual 
pieces of pasta. Mice were trained daily for 5 weeks prior to baseline testing. After stroke, mice 
were tested bimonthly for 9 weeks. The number of pasta breaks per 20-minute session was 
averaged across two consecutive days of testing and normalized to pre-stroke baseline 
performance. 
 
Immunohistochemistry 
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Brains were perfused with 4% paraformaldehyde, cryoprotected, and frozen. Tissue sections 
were incubated in primary antibodies overnight at 4C, following permeabilization and blocking. 
The following primary antibodies were used: rat anti-GFAP (Invitrogen), goat anti-IBA-1 
(Abcam), and rat anti-Glut-1 (Abcam), rabbit anti-Olig2, (Millipore), rabbit anti-NeuN (Abcam), 
and rat anti-CD31 (BD Biosciences). Secondary antibodies were as follows: Alexa Fluor 488 
donkey anti-rabbit, Alexa Fluor 488 donkey anti-rat, and Alexa Fluor 647 donkey anti-rabbit, and 
Alexa Fluor 647 donkey anti-rat, and Alexa Fluor 647 streptavidin (Jackson ImmunoResearch). 
Confocal z-stack images from peri-infarct and contralesional striatum, as well as confocal z-
stack images of ipsilesional cortex, were obtained at 40x magnification. Number of cells and co-
localization of nuclear cell markers through the z-stack was quantified using Imaris Bitplane 
Software, n = 4-5 animals per group.  
  
Axonal sprouting analysis  
Following BDA injection and tissue harvesting, brain sections were stained for BDA using a 
streptavidin-conjugated fluorophore. Confocal z-stack images of each full section were obtained 
at 20x magnification, and maximum intensity projection images were analyzed. Using ImageJ, 
integrated densities were recorded from various brain regions, including white matter, cortex, 
and striatum of both hemispheres. After background subtraction, each section’s intensity data 
were normalized to the integrated density of the section’s BDA injection site. Mean integrated 
density across six sections was calculated and plotted for each animal, n = 4 animals per group. 
 
Nissl Staining and infarct analysis 
Coronal sections were run through ascending alcohol solutions (50%, 75%, 95% and 100%), 
placed in a 1:1 alcohol/chloroform solution for 45 minutes, rehydrated in descending alcohols, 
rinsed in distilled water, and finally stained in a cresyl violet solution. Using ImageJ and MBF 
StereoInvestigator softwares, the volumes of both ipsilesional and contralesional hemispheres 
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or cortices were calculated for a full series of coronal sections through the striatal strokes or 
cortical strokes, respectively. Values were plotted as ratios of the ipsilesional to contralesional 
volumes.  
  
ELISA 
Tissue was collected from peri-infarct striatum 3 weeks after striatal stroke. Striatal tissue was 
dissected in a 1 mm radius around the stroke infarct core, including the core itself, and flash 
frozen in liquid nitrogen. Equal volumes of tissue were homogenized in 100 ml of RIPA buffer 
(Sigma) supplemented with Protease and Phosphatase Inhibitor Tablet (Invitrogen). Tissue was 
incubated in homogenization buffer for 30 minutes on ice, followed by a 5 minute spin at 14,000 
rpm. The supernatant was collected, and total protein concentrations were determined using the 
PierceTM BCA Protein Assay kit (ThermoFisher Scientific). Amount of BDNF protein was 
measured using the BDNF (mouse) ELISA kit (Abnova), per the manufacturer’s instructions.  
 
Statistics 
All reported values represent means and standard errors of the means (SEMs). For PDE10A 
young adult studies, behavioral data were analyzed with general linear model and Tukey’s HSD 
post-hoc test. For all other data, differences between two means were assessed by 
unpaired two-tailed Student’s t-test, and differences among multiple means were 
assessed by one-way analysis of variance (ANOVA) followed by Tukey-Kramer’s post-
hoc tests.  
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Results 
Part I: Striatum-specific PDE inhibition as a pharmacological therapeutic for striatal 
stroke  
 
PDE10A Inhibition Improves Motor Recovery After Striatal Stroke With No Improvement 
in Motor Recovery After Cortical Stroke                     
Mice were given a stroke in the striatum or in the motor cortex in separate cohorts. 
Behavioral testing of forelimb motor function was performed up to 9 weeks post stroke to 
measure exploratory rearing and gait control in forelimb function. 
A competitive inhibitor of PDE10A, TAK-06316, was administered intraperitoneally at 
three escalating doses beginning 5 days post stroke, a time point at which brain sensitivity to 
damage-enhancing effects of plasticity drugs is lost. One week after surgery, the cylinder task, a 
measure of forelimb use in exploratory rearing, indicated that both striatal and cortical stroke 
mice were impaired on the task relative to sham controls (Figure 1A, C). The stroke + 3.0 mg/kg 
dose of TAK-063 produced a tendency toward recovery of function in the affected forelimb in the 
striatal stroke over the 9-week treatment compared with stroke + vehicle controls (Figure 1A, n 
= 8-10 for each treatment group, p = 0.04258). Furthermore, no differences between stroke + 
0.3 mg/kg and 10 mg/kg treatment groups when compared to stroke + vehicle were observed in 
the striatal stroke model. There was no effect of TAK-063 on motor recovery in cortical stroke at 
individual time points and over the 9-week treatment in stroke + 3.0 mg/kg compared with stroke 
+ vehicle controls (Figure 1C, n = 8-11, P = 0.6367).                     
The grid-walking task, a measure of limb use in gait, showed contralateral forelimb 
deficits in stroke + vehicle, stroke + 0.3 mg/kg, stroke + 3.0 mg/kg, and stroke +10 mg/kg 
groups compared with sham + vehicle and sham + 3.0 mg/kg treatment controls (Figure 1B, D). 
In striatal stroke, a significant difference was observed at the individual 6-week (P = 0.04317) 
and 9-week (P = 0.03387) time points in stroke + 3.0 mg/kg versus stroke + vehicle controls. 
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TAK-063 showed a trend toward improvement in overall recovery, with a difference in stroke + 
3.0 mg/kg over the 9-week treatment compared with stroke + vehicle controls (Figure 1B, n = 8-
10 for each treatment group, P = 0.05160). TAK-063 did not enhance recovery of motor function 
in cortical stroke (Figure 1D, n = 8-11, P = 0.9934). Overall, the combined results obtained from 
both behavioral tests indicate that a daily dose of TAK-063 leads to improvement in gait and 
forelimb motor control in striatal stroke but not cortical stroke. 
                     
PDE10A Inhibition Leads to Increases in BDNF                     
PDE10A is predominantly expressed in medium spiny neurons of the striatum. We next 
investigated if treatment with TAK-063 leads to increases in BDNF levels at 3 weeks following 
striatal stroke, a time point where heightened levels of BDNF post- stroke have been reported 
and just before significant behavioral recovery with this drug is observed (Figure 1A, B; 
Supplemental Figure 2). There is a significant loss of BDNF levels in the ipsilateral striatum with 
stroke (Figure 2). Striatal stroke + 3.0 mg/kg of TAK-063 significantly induced BDNF in 
ipsilateral, but not contralateral striatum (Figure 2). This low level of striatal BDNF does not 
change significantly with TAK-063 delivered at a dose that is ineffective in promoting behavioral 
recovery (i.e., at 1.0 mg/kg) (Figure 2A). 
                     
PDE10A Inhibition Alters Motor System Connections after Stroke             
Neural repair after cortical stroke involves axonal sprouting within the ipsilateral peri-
infarct cortex and tissue reorganization in other rodent models of ischemic brain lesions also 
includes axonal sprouting in cortical projections to the contralateral striatum from the stroke site. 
Increases in BDNF promote axonal sprouting after motor cortex and striatal lesions. To 
determine if the improvement in forelimb motor recovery and induction of BDNF in the striatum 
following TAK-063 were associated with axonal sprouting after striatal stroke, the 
neuroanatomical tracer BDA was used to quantitatively map axonal projections from the 
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forelimb motor cortex 6 weeks after stroke, a time of improved motor recovery (Figure 1A, B). 
The pattern of axonal sprouting in stroke and stroke + TAK-063 at the recovery-inducing dose of 
3.0 mg/kg was compared with sham + vehicle and sham + 3.0 mg/kg TAK-063. The density of 
BDA-positive axons was assessed in the striatum for all animals. The mean integrated density 
of labeled axons linearly correlates with axon number. Data was normalized to the integrated 
density of the BDA injection site to account for differences in injection size (Figure 3A-D). 
Striatal stroke causes a loss in the projection from the motor cortex to the contralateral striatum 
(Figure 3C). Stroke + 3.0 mg/kg TAK-063 compared with stroke + vehicle showed significant 
increases (Figure 3C, n = 4-5 for each treatment group, P = 0.0009) in density of BDA positive 
fibers in the contralateral striatum (Figure 3C; data representative of two independent 
experiments). Axonal projections to ipsilateral striatum were mapped; no differences were 
observed in ipsilateral striatum (Figure 3D). These data suggest that TAK-063 either preserves 
the normal pattern of corticostriatal connections or that TAK-063 induces axonal sprouting in the 
partially damaged corticostriatal system and restores the absolute level of this system through 
compensatory axonal sprouting responses. 
                     
Effects of PDE10A Inhibition Post-Striatal Stroke on Angiogenesis 
Angiogenesis plays a role in tissue reorganization in stroke and has been linked to 
recovery in associational studies in humans. There may be an induction of proliferative 
angiogenesis (endothelial cell division) in the absence of changes in the overall morphology of 
the vascular bed. To determine endothelial proliferation in the tissue adjacent to the infarct, mice 
were given a striatal stroke and were treated with a marker of cell proliferation, EdU, for 6 
weeks. Stroke + 3.0 mg/kg TAK-063 increased the total number of proliferative cells in the 
contralateral striatum compared with stroke + vehicle and stroke + 0.3 mg/kg; there was no 
significant difference between stroke + vehicle and stroke 0.3 mg/kg (Figure 4A, upper panel). 
Co-localization of the EdU nuclear signal with the endothelial marker CD31, showed a 
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significant increase in proliferating endothelial cells with stroke + 3.0 mg/kg TAK-063 compared 
with stroke + vehicle (Figure 4A, lower and right panels). Interestingly, in the non-stroke 
(control) condition, TAK-063 induced angiogenesis in the striatum (Figure 4A, lower and right 
panels) (n = 3-5 per treatment group, P < 0.0001). No differences were observed in ipsilateral 
striatum. 
                     
Effects of PDE10A Inhibition on Post-Striatal Stroke Neurogenesis and Gliogenesis     
Angiogenesis is associated with neurogenesis after stroke, and during brain 
development, angiogenesis regulates oligodendrocyte precursor cell (OPC) differentiation and 
myelination. With the angiogenesis induced by TAK-063 after stroke, we examined 
neurogenesis and OPC proliferation in the region of significant angiogenesis (the contralateral 
striatum). There were no differences in a maker of mature neurons, NeuN+ EdU+ cells, in TAK-
063-treated mice compared with controls in either striatal hemisphere (Figure 4B, C). Olig2 is a 
broad marker of cells throughout all but the last stages of OPC differentiation. Quantification of 
Olig2+ EdU+ cells indicates that there is no significant effect of stroke or of TAK-063 treatment 
on OPC proliferation (Figure 4D). 
                     
Delayed PDE10A Inhibition Does Not Affect Infarct Volume                 
Brain volume was assessed between TAK-063 treatment groups as a determinant of 
stroke size for both the striatal and cortical stroke models at 9 weeks post-stroke. At this late 
stage after stroke, the size of the stroke and of any secondary tissue loss can be determined by 
comparing the ipsilateral cerebral striatum to the contralateral cerebral striatum. No differences 
were found in the area of infarct between the striatal stroke groups irrespective of treatment 
(Figure 5).  
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PDE10A Inhibition Does Not Promote Functional Recovery in Aged Mice after Striatal 
Stroke  
    Stroke risk increases with age, and the molecular and cellular responses to stroke differ 
between young and aged brain. To assess the role of selective PDE10A inhibition in promoting 
motor recovery after stroke in aged mice, 3.0 mg/kg of TAK-063 was administered to 18-month 
old mice after striatal stroke. This dose was chosen as it promoted functional improvement, 
BDNF induction, and axonal connectivity in young adult mice. Daily intraperitoneal injection of 
either TAK-063 or vehicle was initiated 5 days after striatal stroke induction and continued for 2 
months. Mice were tested on the grid-walking task, which assesses gait by quantifying 
the  number of steps errors mice make with their stroke-affected forepaw. After stroke, aged 
mice receiving either vehicle or TAK-063 display a statistically significant deficit in performance 
on the gridwalking task compared to sham operated animals (Figure 6, p = 0.0026, p < 0.0001 
for stroke + vehicle and stroke + 3.0 mg/kg groups, respectively). Over the course of 2 months 
of treatment, there was no difference in motor performance between aged mice receiving 3.0 
mg/kg of TAK-063 daily and aged vehicle controls after stroke (Figure 6, p = 0.4121 and p = 
0.2359 1 month and 2 months after stroke, respectively). This suggests that unlike in young 
adult mice, 3.0mg/kg of TAK-063 is not effective at promoting functional recovery after striatal 
stroke in aged mice.  
 
Part II: Cortical PDE inhibition as a therapeutic for cortical stroke  
PDE2 inhibition promotes motor recovery after cortical stroke in young adult mice 
To assess the role of PDE2 inhibition in promoting recovery of motor function following 
cortical stroke, young adult mice (2-3 months old) receiving stroke to forelimb motor cortex were 
treated with daily intraperitoneal injection of either vehicle or 3.0 mg/kg of PDE2A-T1, a novel 
PDE2-specific inhibitor. Two behavioral measurements of motor function were tested 1 week, 5 
weeks, and 9 weeks following stroke: the grid walking task, a measure of gait control, and the 
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cylinder task, a measure of spontaneous forelimb ability. Treatment with 3.0 mg/kg of PDE2A-
T1 improved performance on the grid walking task 1 week and 9 weeks after stroke (Figure 7A, 
p = 0.0478 and p = 0.0452, respectively; n = 12-15 animals per group). Improvement was 
quantified as reduced number of step errors taken with injured forepaw relative to stroke and 
vehicle control. Nine weeks after stroke, mice treated with stroke and PDE2A-T1 recovered to 
sham performance levels, whereas mice treated with stroke and vehicle maintained a 
statistically significant deficit relative to sham animals (p = 0.0143; n = 12-15 animals per 
group). Moreover, a statistically significant main effect of PDE2A-T1 treatment was observed on 
performance in the cylinder task (Figure 7A, p = 0.0429; n = 12-15 animals per group). 
Improvement in the cylinder task was quantified as increased spontaneous use of injured 
forepaw during exploratory rearing. These results suggest a novel role for PDE2-specific 
inhibition in promoting motor recovery after cortical stroke. 
  
PDE2A inhibition promotes motor recovery after cortical stroke in aged mice 
Stroke risk increases with age, and the molecular and cellular responses to stroke differ 
between young and aged brain. To assess the efficacy of selective PDE2 inhibition at promoting 
motor recovery after stroke in aged mice, 19-month old mice receiving stroke to forelimb motor 
cortex were treated daily with intraperitoneal injection of either vehicle or 3.0 mg/kg of PDE2A-
T1. Three behavioral assessments of motor function were tested beginning 1 week after stroke: 
the grid walking and cylinder tasks, tested monthly, and the pasta matrix reaching task, tested 
bimonthly to assess skilled reach ability. Similar to the young adult animals receiving stroke and 
PDE2A-T1, treatment with 3.0 mg/kg of PDE2A-T1 promoted improved performance in the grid 
walking task 1 week and 9 weeks after stroke (Figure 7B, p = 0.0031 and p = 0.0255, 
respectively; n = 8-9 animals per group). PDE2 inhibition also promoted improvement in the 
pasta matrix reaching task 9 weeks after stroke, quantified as an increased number of 
successful reaches through the matrix relative to stroke and vehicle control (Figure 7B, p < 
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0.0001; n = 8-9 animals per group). Unlike the young adult animals receiving PDE2A-T1, no 
statistically significant improvement was observed in the performance of aged mice treated with 
PDE2A-T1 compared to vehicle controls after stroke. However, a non-significant trend towards 
improvement 5 weeks after stroke was observed, and a limited number of aged animals was 
used (Figure 6B, 8-9 aged animals per group vs. 12-15 young adult animals). 
  
PDE2A inhibition increases motor system connections after cortical stroke in aged mice 
To measure the pattern and extent of motor system connections after stroke and vehicle 
or drug treatment, aged mice receiving a unilateral stroke to forelimb motor cortex were injected 
with the neuroanatomical tracer biotinylated dextran amine (BDA) in motor cortex ipsilateral to 
the stroke site. BDA was injected nine weeks after stroke, the time point at which behavioral 
recovery following daily treatment with PDE2 inhibitor was observed. The density of BDA-
positive axons was assessed in ipsilesional cortex for all animals. The mean integrated density 
of labeled axons linearly correlates with axon number. Data was normalized to the integrated 
density of the BDA injection site to account for differences in injection size. Animals treated with 
3.0 mg/kg of PDE2A-T1 showed increased density of axonal labeling in cortex ipsilateral to 
stroke (Figure 8, p = 0.0299; n = 4-5 animals per group), indicating that PDE2 inhibition either 
preserves existing axonal connections or promotes sprouting of new connections following 
stroke. Preservation or remapping of motor system connections might be one potential process 
by which PDE2A-T1 enhances functional recovery after stroke.  
  
PDE2A inhibition does not enhance neuronal, glial, microglial, or vascular cell 
proliferation after cortical stroke in aged mice 
To assess the effect of PDE2 inhibition on cell progenitor pools after cortical stroke, 
aged mice receiving motor cortex stroke were treated with the thymidine analog EdU in drinking 
water. Mice were treated with EdU for days 3-10 after stroke, to assess potential early cell 
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proliferation in response to stroke. PDE2A-T1 treatment began 5 days after stroke and 
continued for 8 weeks. Immunohistochemical labeling of neurons (NeuN), oligodendrocyte 
lineage cells (Olig2), vascular cells (CD31), and microglia (IBA1) was co-located with chemical 
EdU staining. Treatment with PDE2A-T1 was not correlated with increased proliferation of any 
quantified cell type in peri-lesional cortex (Figure 9, p = 0.3946, p = 0.2052, p = 0.9035, and p = 
0.2553, respectively; n = 4-5 animals per group). 
  
PDE2A inhibition does not affect cortical loss or infarct size after cortical stroke in aged 
mice 
Tissue was collected from aged mice receiving photothrombotic stroke to motor cortex, 
along with daily injections of vehicle or 3.0 mg/kg PDE2A-T1, 9 weeks after stroke. At this late 
stage, the size of the stroke and of any secondary tissue loss can be determined by comparing 
the ipsilateral cerebral striatum to the contralateral cerebral striatum. Tissue was Nissl stained 
and imaged, and cortical volumes were quantified using ImageJ. No change in cortical volume 
was observed with PDE2A-T1 treatment after stroke in aged mice (Figure 10, p = 0.0937; n = 5-
6 animals per group). 
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Discussion  
 
Brain region-specific treatments for stroke subtypes  
The above data demonstrate that pharmacological PDE inhibition is a viable therapeutic 
strategy for promoting functional recovery after stroke. Importantly, PDE inhibition is site-specific 
in its role of improving recovery after stroke, with recovery patterns matching the spatial 
localization of each targeted PDE enzyme. The PDE inhibitor TAK-063, which is specific to the 
striatal PDE10A enzyme, promotes recovery of motor function after striatal stroke but not 
cortical stroke in young adult mice. Motor performance after cortical stroke is instead improved 
by treatment with PDE2A-T1, which targets the most highly expressed PDE in cortex. Together, 
these studies consist the first report of a pharmacological therapy for stroke recovery that is 
brain region-specific. 
The adoption of brain region-specific treatments overcomes a key limitation in the 
development of pharmacological therapeutics for neurological disease: unwanted side effects. 
Most notably, early clinical trials attempting to utilize PDE inhibition as a cognitive enhancer 
and/or therapeutic for stroke were hampered by the nausea and emetic responses evoked by 
the PDE4 inhibitors used in these studies [82]. As the maximally expressed PDE isoform in the 
brain, PDE4 remains an attractive target for drug development; however, its high midbrain 
expression resulted in patient nausea and emesis, leading to poor drug tolerability [82]. This 
illustrates the necessity of targeting brain regions that are directly implicated in the diseases or 
neurological contexts under study, though this has proven challenging with systemically 
delivered pharmacological therapeutics. The current study attempts to address this challenge 
via the use of PDE inhibitors spatially restricted to the brain regions affected by each stroke 
subtype. This was achieved by the use of novel, isoform-specific PDE inhibitors with minimum 
activity against other, non-specific PDE isoforms expressed in non-targeted brain regions. Even 
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more precise localization of PDE isoforms and splice variants would aid in the development of 
increasingly specific PDE inhibitors that continue to minimize side effects. 
Stroke in the striatum and in cortical regions governing motor function is very common 
[81], and each of these stroke subtypes involves distinct neuronal circuits and cellular 
architectures. The striatum is home to medium spiny neurons and cholinergic interneurons 
organized in striosomal and matrix compartments, whereas cortical neurons exhibit a much 
greater diversity of subtypes as well as laminar cellular organization [83-84]. These different 
environments could contribute to potential differences in the progression or recovery 
mechanisms induced after stroke. In this study, PDE inhibition promoted an increase in the 
density of motor system axonal connections, possibly via axonal sprouting, in both cortical and 
striatal models of stroke. However, the spatial localization of these connections varied across 
stroke models. Following TAK-063 treatment in striatal stroke, axonal connections were 
observed between ipsilesional motor cortex and contralateral striatum. The pattern observed 
after PDE2A-T1 treatment in cortical stroke was an increase in peri-infarct cortical motor system 
projections, a pattern consistently associated with functional recovery in studies of cortical 
strokes spanning motor regions [13-15, 18-19]. Additionally, while neither TAK-063 nor PDE2A-
T1 promoted neurogenesis or gliogenesis, TAK-063 after striatal stroke increased angiogenesis 
in the contralesional striatum. The differences in recovery mechanisms across these different 
brain regions point to a need for a deeper understanding of the molecular, cellular, and circuit-
level mechanisms governing pathogenesis and recovery following different stroke subtypes. The 
present findings support the possibility of region-specific neural repair, recovery, and treatment 
in stroke that is distinct based on stroke subtype, with subcortical-basal ganglionic stroke 
displaying distinct repair mechanisms and benefiting from a separate drug than cortical stroke. 
This subtype-specific tailoring of treatment might be extended to other common stroke types, 
such as white matter stroke [85].  
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Critical time window for PDE inhibition after stroke  
Ischemic cell death occurs rapidly after stroke onset. Within hours, all cell types within 
the ischemic core die, producing irreversible damage [3, 63]. In this study, treatment with PDE 
inhibitors was initiated at a 5-day delay after stroke, a point that is considered part of the sub-
acute phase of stroke that follows the initial period of post-stroke cell death in rodent models 
[12, 20, 86]. Consistent with this timeline, PDE treatment did not improve functional 
performance through amelioration of cell death or neuroprotection, evidenced by a lack of 
difference in stroke size between vehicle- treated mice and mice receiving TAK-063 or PDE2A-
T1 treatment after stroke. The action of this drug as an enhancer of post-stroke repair and 
plasticity following damage, rather than as a neuroprotective agent, is a key distinction. Despite 
the historical focus of the stroke field on neuroprotection, of the >1000 experimental reports of 
neuroprotection in preclinical studies and the >100 targets tested in clinical trials, no treatments 
or drug regimens have shown enough efficacy to approve their use as protective agents in 
stroke [87-88]. With the failure of neuroprotection as a treatment strategy to date, a focus on 
enhancing and/or reactivating plasticity programs in adjacent, surviving tissue could prove more 
effective clinically compared to attempts at preventing inevitable cell death [89]. Especially with 
the recent, welcome reduction in stroke mortality rates due to improvements in acute care, and 
the consequent growing number of stroke survivors living with chronic disabilities, there is a dire 
need for treatment options that can effectively promote repair and functional recovery despite 
cell death-induced damage [1-4]. 
With this delay in mind, the specific time point to begin PDE inhibition following ischemic 
cell death was carefully chosen. Preclinical studies suggest that enhancing plasticity at times 
when acute injury and death are still occurring destabilizes the brain’s ability to deal with stress 
and thus hinders endogenous neuroprotection, resulting in larger strokes [12, 20, 86]. Studies 
that enhance plasticity and excitability after stroke using tonic GABA inhibition or potentiation of 
glutamatergic AMPAR signaling demonstrate that initiation of treatment sooner than 5 days 
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post-stroke worsens stroke outcome by increasing cell death and infarct size. However, initiation 
of treatment after this sensitive window improves functional recovery with no impact on infarct 
size [20]. In both animal and human studies, early and increased initiation of rehabilitation 
therapies, such as paradigms for forced use of stroke-affected limbs, may worsen long-term 
functional outcomes when compared to treatments initiated later in time after stroke onset [90]. 
What is common to these clinical and preclinical studies is their attempts to promote recovery 
via enhancement of neuronal excitability or activity, whether physiologically by manipulating 
neurotransmitter systems or behaviorally by forced use [91, 153]. The detrimental effects of 
early treatment are thus possibly the result of increasing excitability and promoting energy-
dependent plasticity programs during a time at which excitotoxic cell death and rapid depletion 
of cellular ATP stores are taking place [12]. Together, these observations suggest an inflection 
point in the timeline of stroke, where an initial sensitive period of cell death and damage 
transitions to a period of endogenous repair and plasticity in the more subacute time window 
after stroke. As potentiators of cyclic nucleotide signaling, downstream CREB activation, and 
resulting excitability and plasticity, PDE inhibitors were administered in this study at a 5-day 
delay after stroke. Future work will need to identify an optimal delivery timeline for human 
patients to receive maximum benefit from PDE inhibitors after stroke.  
 
Cellular and molecular mechanisms of PDE inhibition after stroke  
 There are several possible mechanisms of action for PDE inhibition in ischemic stroke. 
First, PDE10A inhibition via daily TAK-063 treatment increases protein levels of BDNF in 
ipsilesional striatum when compared to vehicle treatment after striatal stroke. BDNF is a 
neurotrophic growth factor correlated with functional recovery in several preclinical models of 
stroke [37-39]. For example, potentiation of glutamatergic AMPAR signaling promotes 
behavioral recovery after stroke via induction of BDNF in peri-infarct tissue [37]. Direct delivery 
of BDNF to peri-infarct cortical tissue via sustained hydrogel release improves motor 
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performance and promotes axonal sprouting in animal models of cortical stroke [38]. 
Conversely, mutations in the BDNF gene prevent recovery in both animal models and clinical 
studies of stroke [92]. In brain injury models, including stroke, BDNF is acutely induced in 
affected brain regions; however, this induction only lasts for a limited time window after stroke, 
and BDNF does not cross the blood brain barrier [38-39, 93-94]. Since BDNF is transcribed 
downstream of CREB phosphorylation and activation, PDE inhibition might be one 
pharmacological means for increasing BDNF levels in a sustained, region-specific manner after 
its initial period of induction after stroke [95-98]. Future studies should quantify BDNF levels in 
peri-infarct cortex after cortical stroke and cortical PDE inhibition using PDE2A-T1, particularly 
given BDNF’s role in promoting functional recovery and axonal sprouting in this region. 
Another mechanism of action for PDE inhibition after stroke is axonal sprouting. Axonal 
sprouting within motor or somatosensory systems has been repeatedly demonstrated in many 
rodent and in primate stroke models to correlate with functional recovery [13-15, 18-19]. In this 
model of striatal stroke, PDE10A inhibition increased the density of axonal connections of 
ipsilesional motor cortex with contralateral striatum. This could potentially represent the 
sprouting and rerouting of ipsilesional corticostriatal projections, which would have been 
damaged or lost due to striatal stroke, to the contralateral, uninjured striatum after PDE10A 
inhibition. Similarly, PDE2A inhibition following stroke to the motor cortex increased the density 
of motor system connections in peri-infarct cortex. This pattern could represent the sprouting of 
new axonal connections into adjacent cortical regions spared after stroke, which suggests a 
possible takeover by these surviving regions of motor functions lost due to stroke [18, 51-53]. 
This explanation is consistent with recent studies demonstrating the causal role of CREB 
activation and CREB-mediated transcription on improving behavioral recovery, increasing 
axonal sprouting in peri-infarct cortical regions, and promoting functional reorganization of 
damaged cortical maps in the same rodent model of cortical stroke [18].  
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Alternatively, the increased density of axonal connections observed in both the striatal 
and cortical stroke models may represent a selective sparing of these contralateral connections 
in response to PDE inhibition after stroke. The methodology used for axonal labeling and axonal 
density quantification in this study cannot definitively eliminate this second possible 
interpretation. Future studies might use multiple axonal tracers conjugated to different 
fluorophores to distinguish between pre-stroke axonal connections and those that sprout after 
stroke, as well as more quantitative methods of mapping axonal projections, which could also 
determine potential sprouting directionality [13-14]. These follow-up experiments could more 
definitively determine whether PDE inhibition selectively protects axonal tracts or stimulates 
plasticity and regenerative axonal sprouting. That said, an axonal sprouting effect is consistent 
with a growing body of literature supporting roles for CREB- and BDNF-induced reparative 
plasticity after stroke [18-19, 37-39]. Additionally, the timing of treatment suggests mechanisms 
other than protection [12].  
The potential enhancement of post-stroke axonal sprouting after PDE inhibition suggests 
a possible induction of growth programs within peri-infarct neurons in response to drug 
treatment [13, 99-100]. An initial induction of neuronal growth programs within surviving neurons 
is part of the endogenous cellular response of the brain to stroke [99-100]. This growth state 
comprises transcriptional changes in genes with known functions relevant to axonal sprouting 
and cortical circuit reorganization [13-15, 99-100]. However, this pro-growth state is limited and 
does not persist long after stroke; 21 days after ischemic injury, the transcriptional profile of peri-
infarct sprouting neurons shows distinct changes compared to their 7-day post-stroke 
counterparts, with much of the early growth programs turned off and replaced with up-regulation 
of genes that maintain earlier axonal growth [13]. The axonal sprouting observed in response to 
PDE inhibition suggests a potential action of these PDE inhibitors in enhancing or re-opening 
this axonal pro-growth state. This is likely to occur through the action of CREB, a molecular 
target with known roles in governing plasticity during development, learning and memory, and 
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following multiple models of neurological disease [18, 43-52, 96, 101-106]. Consistent with this 
hypothesis, recent studies have demonstrated that viral up-regulation of CREB in peri-infarct 
excitatory neurons after cortical stroke induces transcriptional changes within these surviving 
cells, including activation of genes with roles in nervous system development and tissue 
development [18]. This suggests a role for CREB in mediating a pro-growth state similar to but 
distinct from developmental growth. 
In striatal stroke, this “growth state” might extend to non-neural cell types—specifically, 
brain endothelial cells. This is supported by data demonstrating enhanced angiogenesis 
observed in contralesional striatum following PDE10A inhibition. This angiogenesis was 
quantified as an increase in the number of cells expressing an endothelial-specific marker that 
had incorporated EdU, which labels proliferating cells, during the first 3-10 days after stroke. 
Angiogenesis, or the growth of new blood vessels from existing vessel branches, has also long 
been correlated with functional recovery after stroke, as well as with axonal sprouting after 
neurological injury [108-111]. After striatal stroke, angiogenesis was observed in the same 
region as axonal sprouting; however, the same two processes were not observed in ipsilesional 
striatum. Recent studies have begun to elucidate the role of the contralateral, uninjured 
hemisphere in recovery after stroke. In larger models of stroke, axonal sprouting is in fact 
observed involving contralateral cortex, striatum, and spinal cord [112]. Additionally, in rodent 
models of ischemic cortical stroke, mice that display spontaneous functional recovery early after 
stroke demonstrate gene expression changes in contralateral cortex that suggest the 
involvement of cAMP signaling pathways in this endogenous recovery [112]. Among these 
differentially regulated genes, PDE10A is down-regulated in the contralateral cortex of these 
spontaneously recovering mice [112]. While the contribution of contralateral tissue to stroke 
recovery is not fully understood, it is possible that pharmacological inhibition of PDEs such as 
PDE10A might have specific roles in promoting recovery mechanisms that involve 
contralesional brain regions, particularly due to the bilateral targeting of these drugs in the brain. 
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CREB: a molecular regulator of recovery downstream of PDE inhibition 
PDE inhibition prevents the hydrolysis of cAMP and cGMP, increasing the availability of 
these intracellular second messengers to participate in signaling pathways that culminate in 
CREB activation [72]. Since BDNF is transcribed downstream of CREB activation, the increase 
in BDNF observed in this study suggests enhanced CREB activation with PDE10A inhibition in 
contralesional striatum. Additionally, the cellular processes promoted by PDE inhibition in both 
striatum and cortex, namely axonal sprouting and striatal angiogenesis, have both been 
demonstrated in multiple models of stroke and other neurological diseases to correlate with 
increased CREB activation and CRE-dependent transcription. In other disease models and in 
learning and memory studies, accumulating evidence has similarly demonstrated the ability of 
PDE inhibitors to increase CREB phosphorylation in the brain. In neuronal culture assays 
utilizing transgenic CRE-β lactamase cells lines, a wide range of PDE inhibitors leads to potent 
enhancement of CRE-mediated transcription in these cells [113]. PDE4 inhibition via Rolipram, 
the subject of various clinical trials, increases hippocampal expression and phosphorylation of 
CREB and the cAMP-dependent, learning and memory-related protein Arc, as well as CREB 
expression following brain injury [114-115]. In models of fetal alcohol syndrome, PDE1 inhibition 
restores phosphorylated CREB levels in visual cortex, in addition to proper visual tuning of 
cortical maps [116]. Together, these data demonstrate that systemic delivery of PDE inhibitors 
can effectively enhance CREB phosphorylation in the brain, and that CREB activation is an 
important mechanism of action of these drugs. 
The key role for CREB activation in stroke recovery has been highlighted in several 
recent studies [18-19, 21, 117]. CREB was shown to play a causal role in regulating behavioral 
recovery after stroke, acting as a molecular switch that can be turned on or off to mediate 
functional improvement [18]. In these studies, selective inactivation of neurons in which CREB 
was induced results in a loss of the motor gains observed after CREB activation, while 
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subsequent release of this inactivation reinstates the improvement. Functional recovery in this 
previous study also correlated with increases in axonal sprouting, which is in line with the 
current results described following PDE inhibition, as well as functional reorganization of cortical 
maps. In other studies, the molecular learning and memory target CCR5, the chemokine 
receptor that binds HIV, was shown to promote functional recovery after stroke when genetically 
knocked-down in neurons or pharmacologically antagonized with the FDA-approved drug 
maraviroc [19]. Importantly, this functional improvement accompanied genetic up-regulation of 
CREB in neurons, as well as enhancements in axonal sprouting and dendritic spine plasticity. 
As discussed previously, potentiation of glutamatergic AMPAR signaling also improves 
functional recovery after stroke in a BDNF-dependent manner, suggesting a role for increased 
CREB activation in this process [21]. Together, these studies demonstrate a convergence of 
mechanism onto CREB activation by the action of many molecular learning and memory 
systems targeted as therapeutics for stroke. The current study demonstrates a pharmacological 
method for targeting CREB in the brain after stroke using a systemically injected drug and thus 
could have important clinical potential. 
 
Age-specific effects of PDE inhibition after stroke  
    Most preclinical stroke studies are conducted using young adult animals [118]. However, 
stroke predominantly affects the aging population, with stroke incidence markedly increasing 
beyond the age of 65 [119]. This suggests that aged models of stroke better represent clinical, 
human stroke. Indeed, aged mouse models are more likely to incorporate common, age-related 
stroke comorbidities, such as hyperlipidemia, obesity, and hypertension, which contribute to the 
severity of stroke pathogenesis [118]. Aged mouse models also more closely represent the 
aging brain’s reduced capacity for plasticity, a consequence of the structural and functional 
changes demonstrated to affect brain cell types with age [120-122]. These factors make aged 
mice a stronger model system to test stroke therapeutics preclinically. In this study, 18 to 19-
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month old C57BL mice were used in addition to young adult mice to more accurately model 
human stroke. This represents a mouse age range at which senescent biomarkers are routinely 
observed, and roughly correlates to 60 years of age in humans [123-124]. (In contrast, the 
young adult studies were performed in 3-month old mice, which correlates to 20 years of age in 
humans.)  
    An important result of this work is that TAK-063 treatment, which inhibits striatal PDE10A, did 
not promote recovery of function in aged mice after striatal stroke despite its efficacy in young 
adult mice. This discrepancy in therapeutic efficacy might be attributed to a variety of factors. 
First, since the severity of stroke increases with age [99, 120, 125-128], greater initial damage in 
the aged brain might have created a larger barrier to recovery not overcome with TAK-063 
treatment. In aged models of stroke, accelerated lesion and glial scar formation, reduced blood 
brain barrier integrity, greater white matter and blood vessel degeneration, increased oxidative 
damage, and elevated, more widespread inflammatory responses contribute to greater degrees 
of injury and more sustained deficits after stroke [126-134]. At least some of these aging 
mechanisms might act with region specificity in the brain. For example, occlusion of the middle 
cerebral artery, which damages both cortical and striatal tissue, produces accelerated striatal 
but not cortical infarcts in aged relative to young adult mice [130]. In this model, the aged 
striatum but not cortex also displays higher levels of mitochondrial dysfunction, oxidative stress, 
and pro-oxidant/antioxidant imbalances in response to stroke, contributing to a potential 
subcortical ischemic vulnerability with age [130]. Thus, the treatment dose and duration used for 
young adults might not have promoted recovery in aged mice experiencing accelerated or more 
severe post-stroke damage. This possibility should be further explored.  
Second, as noted, the capacity of the aged brain for repair and regeneration diminishes 
with age [120-122, 134]. It is thus possible that the mechanisms governing the observed 
recovery in young adult animals were not induced to the same extent in aged animals, limiting 
recovery. In this study, TAK-063 treatment promoted angiogenesis and axonal sprouting after 
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striatal stroke in young adult animals. However, both these repair processes exhibit age-
dependent decline [13, 15, 19, 136-142]. For example, lower angiogenic responses have been 
consistently reported in preclinical and clinical studies of aged stroke, hypoxia, and peripheral 
artery occlusion [136-141]. This reduced angiogenesis can in part be explained by impaired 
endothelial cell function (namely, lower nitric oxide production and acetylcholine-dependent 
vessel dilation), as well as decreased endothelial cell VEGF receptor expression, resulting in 
attenuated responses to pro-angiogenic factors [136-139]. In fact, this decline in VEGF receptor 
expression might exhibit region-dependency within the brain [136]. On the other hand, axonal 
regeneration and sprouting in response to CNS injury also diminishes with age [13, 15, 19, 142]. 
For example, genetic PTEN deletion, which typically promotes axonal regeneration after nerve 
injury in young adults, does not promote long-range growth or protect against degeneration after 
spinal cord injury in aged mice [142]. After ischemic stroke, axonal growth-promoting genes are 
induced at later time points and growth-inhibiting genes/proteins are induced earlier and to a 
greater extent in aged mice relative to young adult mice [13, 15, 19]. It is thus possible that the 
lack of recovery observed in aged mice could in part be due to diminished axonal sprouting, as 
well as angiogenesis, processes with demonstrated impact on functional recovery after stroke. 
Further studies are necessary to compare the extent of axonal sprouting and angiogenesis 
induced in the striatum of aged versus young adult mice after stroke and TAK-063 treatment.  
Lastly, age-dependent alterations in the signaling cascade underlying TAK-063’s 
mechanism of action might have rendered this drug treatment less effective at promoting 
recovery in the aging brain. Accumulating evidence in both human and animal models have 
identified age-related, brain region-specific changes in the cyclic nucleotide to CREB signaling 
cascade at each level of the pathway, including alterations in GPCR, adenylyl cyclase, 
cAMP/cGMP, PDE, PKA/PKC, and CREB expression and/or activity [143]. Of note, PDE 
enzymes are reported to exhibit more resistance to pharmacological modulation during aging, 
with rolipram binding activity reduced by 22-25% in the aging striatum and cortex (but not 
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cerebellum) of nonhuman primates, and sildenafil activity lowered by half in aged rodent models 
of stroke [144, 145]. In aging D1 neurons, dopamine agonists are less effective at inhibiting the 
binding of PDE inhibitors to their PDE substrates, suggesting a depression of cyclic nucleotide-
dependent signaling cascades with age [144]. Downstream of this, the DNA binding activity of 
CRE has been reported to decrease with age, particularly in the basal forebrain and striatum 
[146]. Age-dependent changes in cyclic nucleotide-protein kinase-CREB signaling are more 
pronounced when the aged brain is challenged with stress or injury. After traumatic brain injury, 
aged mice show larger reductions in cAMP levels compared to young mice, and this correlates 
with reduced LTP and cognitive performance [147]. Aged mice also experience lower injury 
thresholds for TBI-induced cAMP reductions, as well as less complete recovery of cognitive 
abilities following PDE inhibitor treatment [147]. In models of neurotoxic injury to the striatum, 
compensatory BDNF production in the lesioned striatum is not observed in aged animals 
despite an observed BDNF increase in young adult mice [148]. This lack of BDNF induction is 
region-specific, as the same neurotoxic injury to the midbrain leads to BDNF increases in both 
young adult and aged mice [148]. Further, regional declines in BDNF signaling with age have 
been reported to depend on brain region-specific changes in regulators of BDNF transcription 
and post-transcriptional processing, as well as regional changes in phosphorylation of BDNF’s 
high-affinity receptor TrkB [135]. Additional studies are needed to identify potential age-
dependent changes in cyclic nucleotide, CREB, and/or BDNF regulation after striatal stroke. 
However, it remains possible that the lack of recovery promoted by TAK-063 might involve an 
age-related reduction in cyclic nucleotide pathways, CREB activity, and/or BDNF signaling, 
some of the key molecular targets affected by PDE inhibition.  
Together, these age-dependent differences highlight the need for a revised PDE 
inhibition treatment strategy for striatal stroke. This might include increasing the dose 
administered to aged animals beyond that of young adults, or perhaps combining TAK-063 
treatment with other drugs or rehabilitative therapies to effect maximum functional recovery. 
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Previous studies using the PDE5 inhibitor sildenafil as a treatment for cortical stroke 
demonstrated that aged mice required 5 times the dose of young adults to achieve functional 
recovery with treatment (10 mg/kg versus 2 mg/kg; 3 mg/kg was administered in the current 
study) [145]. In these earlier studies, aged mice demonstrated only half the increase in cyclic 
nucleotide levels as young adult mice did with the same dose of PDE inhibitor [145]. In other 
studies of cortical stroke, aged mice required a combined treatment of BDNF and a BDNF-
inducing AMPAkine drug to promote similar functional recovery and induce BDNF levels to 
those observed in young adult animals receiving BDNF treatment alone [149]. This suggests 
that a certain threshold for BDNF potentiation and/or upstream CREB activation exists to 
observe functional recovery in aged mice, which might not have been reached in this study with 
the particular dose of drug used. Further studies are required to determine the optimal TAK-063 
dosage to use for aged mice, as well as how well tolerated these higher doses of drugs are. 
Alternative strategies might include combining a more effective TAK-063 dose with a 
rehabilitation paradigm such as forced paretic limb use, a behavioral therapy demonstrated to 
increase measures of brain plasticity after stroke including peri-infarct neuronal excitability, 
neurogenesis, and axonal sprouting [91, 150-154].  
Despite the challenges associated with repairing the aged brain after stroke, the second 
drug tested in this study, PDE2A-T1, was able to promote functional recovery and tissue-level 
repair in aged mice after cortical stroke. Several key distinctions can be made between the 
PDE2A-T1 and TAK-063 studies which might account for this difference. First, the brain regions 
injured in each study varied considerably, with the PDE2A-T1 study conducted in mice receiving 
cortical strokes, and the TAK-063 study conducted in mice receiving subcortical, striatal strokes. 
As discussed above, there is evidence to support that a number of age-related mechanisms 
associated with increased stroke severity, lower plasticity capacity, and potentially reduced drug 
efficacy are heightened in subcortical brain regions relative to cortical areas. It is thus possible 
that a subset of cellular and molecular processes involved in stroke damage or recovery might 
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be differentially regulated in striatum versus cortex and/or differentially targeted by regional PDE 
inhibition. Further studies comparing the pathophysiology of stroke in different brain regions are 
needed to explore this hypothesis and to develop more effective treatments for stroke subtypes. 
Second, the specific targets of the two PDE inhibitors in this study differ, which might have 
implications for the molecular mechanisms induced by these drugs. PDE2A-T1 targets the 
cGMP-stimulated PDE2 enzyme, which exhibits bias towards cGMP hydrolysis in the brain, 
while TAK-063 targets PDE10, a dual-substrate enzyme with higher cAMP specificity [72, 73]. 
While both cyclic nucleotides act in signaling cascades that activate CRE-mediated 
transcription, it is possible that additional mechanisms induced by cGMP potentiation underlie 
some of the drug-induced recovery observed after cortical stroke and PDE2A-T1 treatment [69-
70, 155]. In the brain, the NO/cGMP pathway is associated with neurogenesis, angiogenesis, 
and axonal sprouting [145, 155-158]. Notably, cGMP levels and activity of the nitric oxide/cGMP 
pathway are reduced in the aging brain, and after stroke, aged mice exhibit decreased cortical 
levels of cGMP relative to young adult mice [143, 145, 159-161]. Additional studies might 
investigate differences in cGMP- versus cAMP-mediated mechanisms of repair after stroke, and 
the extent to which each cyclic nucleotide signaling system is potentiated after TAK-063 and 
PDE2A-T1 treatment. Lastly, it should be noted that the technical method of stroke production 
varied across studies, with cortical strokes produced via photothrombosis and striatal strokes 
produced via localized vasoconstrictor injection. Any variations in the pathophysiology induced 
by each respective stroke model, or the potential differing sensitivity of the behavioral 
assessments towards detecting deficits from each stroke model, should be taken into account 
for a more comprehensive comparison of the two PDE inhibitors.  
Together, these aged mouse studies highlight the importance of validating preclinical 
findings in the appropriate disease models. This would aid in the development of stroke 
therapeutics that are met with more clinical success. It is possible that the use of young adult 
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animals in preclinical stroke research is one reason for the failure of many stroke drugs in 
clinical trials, despite demonstrated preclinical promise [118, 161-162]. 
 
Future directions  
The current studies identified axonal sprouting and angiogenesis as neural plasticity 
measures potentially induced by CREB activation with PDE inhibition after stroke. In addition to 
these mechanisms, CREB is a known enhancer of neuronal excitability [41, 42], and enhancing 
neuronal excitability specifically has been shown to promote functional recovery after stroke [3, 
23, 18, 20-21, 149, 163-166]. Future studies could aim to understand the effects of PDE 
inhibition specifically on peri-infarct and contralateral excitability after stroke. This can be 
investigated at multiple scales, such as the study of dendritic spine plasticity and turnover, the 
electrophysiological properties of various neuronal cell types in the PDE inhibition territory, or 
circuit-level excitability via calcium imaging. These excitability changes can also be investigated 
in the context of combined neurorehabilitative and drug treatment studies, to probe for a 
potential synergistic effect of behavioral and pharmacological enhancements in excitability and 
recovery after stroke. 
However, CREB activation is just one potential mechanism of PDE inhibition 
action.  PDEs and cyclic nucleotides are involved in a wide variety of signal transduction 
pathways outside of those that activate CREB and CRE-mediated transcription, some of which 
also regulate cellular excitability [70-73, 79, 95]. Alternative molecular effectors known to act 
downstream of PDE inhibition include: cyclic nucleotide-gated ion channels (CNGs), the 
exchange protein activated by cAMP (Epac), mitogen activated protein kinases (MAPK), 
Ras/Raf and ERK kinases, and cAMP-GEF proteins, which activate the RAP-1 pathway [167-
171]. Due to the complex nature of intracellular signaling, these alternative and/or 
complementary mechanisms of action for PDE inhibition in stroke should also be considered. 
While the examination of these separate signaling pathways and mechanisms is outside the 
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scope of this current study, investigating these other systems are potential targets for future 
work and might uncover additional cellular and molecular mechanisms for neural repair after 
stroke.  
Additional work might also focus on characterizing the cellular and subcellular 
compartmentalization of PDEs, as well as the action of increasingly specific PDE inhibitors, in 
the brain. For example, the novel PDE10A inhibitor used in this study, TAK-063, is known to 
preferentially increase cyclic nucleotide expression in the striatal D2 medium spiny neurons 
(MSNs) and only partially in D1 MSNs [172]. In other words, beyond its region-specific 
properties, TAK-063 is also a neuronal subtype-biased drug. In models of neuropsychiatric and 
Huntington’s diseases, this property allows TAK-063 to restore the pathological imbalance in 
neurotransmission observed between striatal D1 and D2 in preclinical models of these diseases, 
leading to TAK-063 induced behavioral improvement [172]. Imbalances in the D1/D2 system are 
implicated in various hypokinetic and hyperkinetic movement disorders resulting from lesions to 
the basal ganglia, including the striatum [174]. These disorders can present following ischemic 
lesions to these regions, sometimes at a delay after stroke [175]. It is possible that an additional 
mechanism of action of PDE10A inhibition via TAK-063 treatment might be to restore a potential 
imbalance in this striatal system. As noted, aging D1 neurons exhibit depressions in cAMP 
signalling [144]; identification of PDE10A inhibitors that function in D1 rather than or in addition 
to D2 MSNs might be a more effective therapeutic for aged striatal stroke. In addition to 
investigating the effect of TAK-063 on D1/D2 MSN balance after stroke, future studies could 
also identify whether the cortical PDE inhibitor used in this study, PDE2A-T1, also exhibits any 
cell type selectivity. These cortical studies might aim to identify potential cell type- and neuronal 
subtype-specific expression of PDEs in cortex, whether PDE expression patterns change with 
stroke, and the potential role of PDE inhibitors in regulating the excitation-inhibition balance 
after stroke. Characterizing the distribution of PDEs and the effects of PDE inhibitors in this way 
would lead to a better understanding of the mechanisms underlying PDE inhibition and 
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potentially aid in the development of increasingly specific PDE inhibitors that target these 
differentially localized PDE isoforms. 
Currently, selective PDE inhibitors are being investigated as potential therapeutics for a 
wide range of neurological diseases, including schizophrenia, Alzheimer’s disease, Huntington’s 
disease, and even malignant brain tumors [71-73]. Outside of the brain, PDE inhibitors have 
found clinical success in ameliorating symptoms of pulmonary hypertension, acute cardiac 
failure, and erectile dysfunction [73]. With an increased understanding of the mechanisms of 
PDE inhibitor action, the physiological roles and compartmentalization properties of different 
PDE isoforms [176-177], and the dynamic changes in cyclic nucleotide signaling and 
localization during health and disease [178-179], more targeted PDE inhibitors can be 
developed and applied strategically towards the treatment of peripheral and brain disease, 
including stroke [71-73, 77-80].  
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Figures  
Figure 1: Functional effect of TAK-063 on forelimb use and gait post-striatal and cortical 
stroke in young adult mice 
  
Figure 1: (A) In post-striatal stroke of the left hemisphere, the Cylinder task revealed that Stroke 
+ 3.0 mg/kg versus Stroke + Vehicle had an overall increased right paw use over the 9-week 
treatment; *P = 0.04258. (B) Differences in gait observed for Stroke + Vehicle versus Stroke + 
3.0 mg/kg at 6 weeks; *P = 0.04317 and at 9 weeks; *P = 0.03387 in post-striatal stroke. For 
overall differences between Stroke + Vehicle versus Stroke + 3.0 mg/kg, P = 0.05160. (C) In 
post-cortical stroke of the left hemisphere, the forelimb task revealed no differences in Stroke + 
Vehicle versus treatment groups. (D) Differences in gait were also not observed in Stroke + 
Vehicle versus treatment groups in post-cortical stroke. Error bars represent mean ± SEM for n 
= 8-10 per group in striatal stroke model and n = 8-11 in cortical stroke model. Data are reported 
as difference from baseline. Data were analyzed by GLMs with Tukey’s HSD. 
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Figure 2: TAK-063 treatment-mediated alterations in BDNF expression in striatal tissue 
  
 
 
Figure 2: (A) BDNF expression levels measured with tissue ELISA showed a decrease at 3 
weeks post-striatal stroke in striatal tissue, ipsilateral to the infarct. Treatment with TAK- 063 
resulted in a significant increase in BDNF levels in the Stroke + 3.0 mg/kg versus Stroke + 
Vehicle group in ipsilateral striatum; P = 0.005, corrected for multiple comparisons. Error bars 
represent mean ± SEM for n = 10 per group. (B) Treatment with TAK-063 resulted no 
differences in BDNF levels in Stroke + Vehicle compared to other treatment groups in 
contralateral striatum. Error bars represent mean ± SEM for n = 3-4 per group. 
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Figure 3: Motor connections post-striatal stroke and TAK-063 treatment  
 
 
Figure 3: (A) Image of BDA-labeled connections from the motor cortex of Stroke + Vehicle and 
(B) Stroke + 3.0 mg/kg mice. Arrow shows labeled axonal fibers. Data were normalized to 
integrated density of the BDA injection site for each treatment group. (C) Total BDA-positive 
fibers were increased at 6 weeks post-striatal stroke in the contralateral cortical tissue in Stroke 
+ 3.0 mg/kg versus Stroke + Vehicle; *P = 0.0009. (D) Ipsilateral striatum showed no differences 
between groups. Error bars represent mean ± SEM for n = 4-5 per group. Scale bar = 50 µm 
and applies to all photomicrographs. 
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Figure 4: Effects of PDE10A inhibition on angiogenesis, neurogenesis, and gliogenesis in 
post-striatal stroke 
 
Figure 4: (A, upper panel) Total EdU+ cells were increased at 6 weeks post-striatal stroke in 
contralateral striatum in Stroke + 3.0 mg/kg versus Stroke + Vehicle; *P < 0.0001. (A, lower 
panel) EdU+ CD31+ cells were increased at 6 weeks post- striatal stroke in striatal tissue 
contralateral to the infarct. Representative images of EdU+CD31+ cells in contralateral striatum. 
Top left: Sham + Vehicle, bottom left: Sham + 3.0 mg/kg, top right: Stroke + Vehicle, bottom 
right: Stroke + 3.0 mg/kg. (A, lower panel) Treatment with TAK-063 resulted in a significant 
increase in EdU+ CD31+ cells in the Stroke + 3.0 mg/kg versus Stroke + Vehicle group, *P = 
0.0201. No differences were observed in Sham + 3.0 mg/kg and Stroke + 3.0 mg/kg. Error bars 
represent mean ± SEM for n = 3-5 per group. (B, C) NeuN+ EdU+ cells showed no differences 
between groups 6 weeks post-striatal stroke in contralateral and ipsilateral striatum. Error bars 
represent mean ± SEM for n = 3 per group. (C) Olig2+ EdU+ cells showed no differences 
between groups in ipsilateral striatum. Error bars represent mean ± SEM for n = 3-4 per group. 
Scale bar = 50 µm and applies to all images.  
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Figure 5: Degree of infarct size in TAK-063-treated mice 
  
Figure 5: (A, C) Top panel shows Nissl-stained brain tissue section from representative stroke 
groups at 10 weeks post- stroke. The arrow indicates the area of striatal infarct, with no 
observable differences between groups. The lower panel quantifies the degree of stroke. The Y-
axis indicates the normalized ratio of the ipsilateral stroked hemisphere over the contralateral 
non-stroked hemisphere. Data is shown are measurements at -0.22 mm to -0.82 mm from 
Bregma. Stroke leads to a loss of tissue volume in the hemisphere ipsilateral to the stroke. 
Lower values indicate loss of tissue volume. Data show that there was no effect between the 
treatment groups; however (B, C) Stroke + 3.0 mg/kg and Stroke + Vehicle group shows a 
significant difference compared to Sham + Vehicle; *P = 0. 0146; *P = 0.0053; n = 8- 10 per 
group. (D) The combined stroke groups versus the combined sham control groups (n =18 and 
32, *P = 0.001). All p-values corrected for multiple comparisons. Error bars represent mean ± 
SEM. Scale bar = 50 µm and applies to all images. 
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Figure 6: Functional effect of TAK-063 on gait post-striatal stroke in aged mice 
 
 
Figure 6: In aged mice, 
PDE10A inhibition via daily 
TAK-063 injection does not 
improve gait abnormalities 
made with the affected forelimb 
after stroke (p = 0.4121 and p = 
0.2359 for 1 month and 2 
months after stroke, 
respectively). Two-way ANOVA 
with Tukey multiple 
comparisons test. Data shown 
are means and SEMs, 12-17 
animals per group. 
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Figure 7: Functional effect of PDE2A-T1 on gait, spontaneous forelimb use, and skilled 
reach after cortical stroke in young adult and aged mice 
 
Figure 7: (A) In young adult mice receiving cortical stroke, PDE2A-T1 reduces gait abnormalities 
made with affected forelimb 1 week and 9 weeks after stroke (p = 0.0478 and p = 0.0452, 
respectively) and increases spontaneous use of affected forelimb during exploratory activity (p = 
0.0429). (B) In aged mice receiving cortical stroke, PDE2A-T1 reduces gait abnormalities with 
affected forelimb 1 week and 9 weeks after stroke (p = 0.0031, p = 0.0555, and p = 0.0255, 
respectively), and increases the number of successful reaches through a skilled reach matrix (p 
< 0.0001). PDE2A-T1 does not improve spontaneous forelimb ability in aged animals 1, 5, or 9 
weeks after stroke (p > 0.9999, p = 0.5183, and p > 0.9999, respectively). Two-way ANOVA 
with Tukey and/or Sidak multiple comparisons test. Data shown are means and SEMs, 12-15 
young adult animals per group, 8-9 aged animals per group.    
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Figure 8: PDE2 inhibition increases peri-lesional axonal connections in aged mice after 
cortical stroke 
 
  
Figure 8: Amount of BDA-labeled axons in ipsilateral cortex is increased following cortical stroke 
and daily PDE2A-T1 treatment (p = 0.0299). Integrated density, a measure of fluorescence 
intensity, of BDA-labeled axons was quantified using ImageJ. Data were normalized to 
integrated density of BDA injection site. Data shown are means and SEMs, n = 4-5 animals per 
group. 
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Figure 9: PDE2 inhibition does not enhance early-phase cell progenitor proliferation in 
peri-lesional cortex after stroke in aged mice 
 
Figure 9: Mice were dosed with EdU 3-10 days after stroke. Number of EdU-incorporated cells 
co-labeled with NeuN, Olig2, IBA1, and CD31 in peri-lesional cortex does not change with daily 
treatment of PDE2A-T1. Data shown are means and SEMs, n = 4 animals per group. 
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Figure 10: Degree of infarct size in PDE2A-T1 treated aged mice 
 Figure 10: PDE2A inhibition via daily PDE2A-T1 
injection does not alter the size of cortical infarcts 
after stroke in aged mice. The Y-axis indicates the 
normalized percentage of the ipsilateral stroked 
hemisphere over the contralateral non-stroked 
hemisphere. Data shown are means and SEMs, n 
= 5-7 animals per group. 
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